Modification of the terms of authorisation of the feed additive consisting of canthaxanthin for chickens for fattening, minor poultry species for fattening, laying poultry and poultry reared for laying, ornamental fish and ornamental birds and ornamental breeder hens to include canthaxanthin produced with CBS 146148 (DSM Nutritional Products Ltd.).

Following a request from the European Commission, the European Food Safety Authority was asked to deliver a scientific opinion on the proposed modification of the terms of the authorisation of canthaxanthin, regarding the addition of a new production route, by the yeast CBS 146148. The additive is already authorised as sensory feed additive for use in feed for chickens for fattening, minor poultry species for fattening, laying poultry, poultry reared for laying, ornamental fish, ornamental birds and ornamental breeder hens. The Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) concludes that canthaxanthin produced with CBS 146148 is considered safe for the target species, the consumer and the environment under the current authorised conditions of use.

Modification of the terms of authorisation of the feed additive consisting of a preparation of canthaxanthin (CAROPHYLL® Red 10%) for breeder hens to include canthaxanthin produced with CBS 146148 (DSM Nutritional Products Ltd.).

Following a request from the European Commission, the EFSA was asked to deliver a scientific opinion on the proposed modification of the terms of the authorisation of the feed additive consisting of a preparation of canthaxanthin (CAROPHYLL® Red 10%), regarding the addition of a new production route, by the yeast CBS 146148 and to modify the additive specifications by substituting ethoxyquin by 4.4% butylated hydroxytoluene (BHT) and increasing the limit for dichloromethane to 80 mg/kg. The additive is already authorised as zootechnical feed additive for breeder hens.

Multiomics dissection of human RAG deficiency reveals distinctive patterns of immune dysregulation but a common inflammatory signature.

Human recombination-activating gene (RAG) deficiency can manifest with distinct clinical and immunological phenotypes. By applying a multiomics approach to a large group of -mutated patients, we aimed at characterizing the immunopathology associated with each phenotype. Although defective T and B cell development is common to all phenotypes, patients with hypomorphic variants can generate T and B cells with signatures of immune dysregulation and produce autoantibodies to a broad range of self-antigens, including type I interferons.

Distinct clinical patterns in AQP4-IgG- positive NMOSD patients vs. Seronegative: Insights from a single-center study in Argentina.

Background: Distinct clinical course patterns have been identified between AQP4-IgG-positive and AQP4-IgG-negative NMOSD patients.

Objectives: This study aimed to evaluate the differences between AQP4-IgG-seropositive and AQP4-IgG-seronegative NMOSD patients in a single centre in Argentina.

Methods: We performed a retrospective cross-sectional study of 108 NMOSD patients in the city of Buenos Aires, Argentina.